STAT+: Exemption of rare disease therapies in drug-pricing pilots would wipe out huge savings, analysis finds

AI justification

Exclusion of rare disease therapies undermines equitable access to healthcare, violating rights and harming vulnerable groups. | While the Medicare pilot program to lower drug prices aligns with goals of improving healthcare access and reducing inequalities, the exclusion of rare disease therapies introduces significant ethical concerns. It risks prioritizing cost savings over equitable access to life-saving treatments, violating the right to health for vulnerable populations. The net impact lea